Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
|Articles|September 13, 2021
Pharmacy Clinical Pearl of the Day: Crohn Disease
Author(s)Saro Arakelians, PharmD
Crohn disease causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
Advertisement
Clinical Pearl of the Day: Crohn Disease
Crohn disease is a type of inflammatory bowel disease.
Explanation
- Crohn disease causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
- Symptoms include diarrhea, fever, fatigue, abdominal pain, cramping, blood in the stool, mouth sores, reduced appetite, and weight loss.
- The condition could be genetic or caused by an immune system reaction.
- Risk factors include age, ethnicity, family history, cigarette smoking, and non-steroidal anti-inflammatory drugs.
- Treatment includes anti-inflammatory drugs, such as corticosteroids and oral 5-aminosalicylates; immune system suppressors such as azathioprine and methotrexate; biologics such as Remicade, Tysarbi and Stelara; antibiotics such as Cipro and Flagyl; and anti-diarrheal medications, pain relievers, vitamins, and nutrition therapy.
References
Advertisement
Related to this article
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5